Lindo Life Science
Advancing innovation in
infection control
Lindo Life Science is developing a portfolio of medical devices that are redefining how the world prevents, manages and responds to infection in critical care environments.
At the centre of this effort is Lindo Tube, which pioneers safe, light-based antimicrobial technologies to reduce healthcare-acquired infections.
About Lindo Tube
Lindo Tube is redefining critical care. This first-in-class antimicrobial blue light (aBL) endotracheal tube is engineered to prevent ventilator-associated pneumonia (VAP) at the source.
Developed in collaboration with the Number 1 hospital in the world Mayo Clinic, Lindo Tube delivers a breakthrough solution to one of the most urgent and costly problems in healthcare.
In 2025, Lindo was awarded $2 million in matched funding under the Australian Government’s Industry Growth Program to advance the development of Lindo Tube.
This funding supports a $4 million total project value that will advance the Lindo Tube from Technology Readiness Level (TRL) 4 to TRL 7, enabling the device to enter preclinical and clinical trials in both Australia and the United States.
Breakthrough simplicity
Hospital-acquired infections are a $28 billion burden in the United States alone.
Ventilator-associated pneumonia accounts for nearly 40% of all hospital-acquired pneumonia cases in acute care and remains one of the most lethal complications in critical care settings.
Lindo Tube addresses this challenge head-on. The antimicrobial blue light system operates continuously and automatically — no chemicals, no workflow disruption and no added labour.
It integrates seamlessly into standard endotracheal tube assemblies, targeting microbial biofilm formation with precision.
Proven technology addressing antimicrobial resistance
Powered by patented multi-wavelength, high-intensity aBL (MWHI® aBL), Lindo Tube deactivates pathogens including drug-resistant bacteria and disrupting the formation of biofilm, without harming human tissue or contributing to antimicrobial resistance (AMR).
Bench testing has demonstrated up to 99.9% pathogen reduction in minutes.
Currently designed in collaboration with Mayo Clinic, the Lindo Tube is now advancing to alpha prototype stage before it progresses to real-world clinical trials in ICU conditions. Lindo Tube is supported by strong IP protections, a global regulatory pathway and an expert-led advisory board.
Made for global health resilience
Lindo Tube is designed, engineered, and tested in Australia, but built for global deployment. Our commercialisation strategy is focused from day one on international markets — starting with the United States.
The US addressable market for endotracheal tubes is estimated at US$214 million, with strong and growing demand for safer airway management in critical care . More broadly, antimicrobial resistance now represents a global health security threat and is expected to create a US$12 billion market for solutions that can reduce pathogen load without driving resistance.
Lindo Tube is positioned to serve both — offering a scalable, clinically integrated solution for ventilated patients while contributing to global efforts to reduce avoidable antibiotic exposure.
We are committed to operating in the US market and bringing Lindo Tube into frontline healthcare environments. Lindo Life Science is building practical, science led technologies that support global health resilience, reduce system burden, and strengthen infection control where it is most urgently needed.
Advanced infection control
To find out more about Lindo Life Science or to enquire about investment opportunities, please get in touch info@lindo.group